File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/onc.2012.159
- Scopus: eid_2-s2.0-84874766439
- PMID: 22614012
- WOS: WOS:000316454500004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression
Title | Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression |
---|---|
Authors | |
Keywords | iron intestinal cancer 24p3 NGAL |
Issue Date | 2013 |
Citation | Oncogene, 2013, v. 32, n. 10, p. 1233-1239 How to Cite? |
Abstract | Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cancer. Functionally, LCN2 has a number of different activities that may contribute to its oncogenic potential, including increasing matrix metalloproteinase activity, control of iron availability and stimulating inflammation. In this report, we examined APCmin intestinal tumorigenesis in an LCN2-deficient background. We found that the loss of LCN2 increased tumor multiplicity specifically in the duodenum, suggesting a potential tumor-suppressive activity. Concurrently, however, LCN2 increased the average small intestinal tumor size particularly in the distal small intestine. We found that this increase was correlated to tumor iron(II) content, suggesting that an iron-scavenging role is important for LCN2 oncogenic activity in the intestine. © 2013 Macmillan Publishers Limited. |
Persistent Identifier | http://hdl.handle.net/10722/292231 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.334 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Reilly, P. T. | - |
dc.contributor.author | Teo, W. L. | - |
dc.contributor.author | Low, M. J. | - |
dc.contributor.author | Amoyo-Brion, A. A. | - |
dc.contributor.author | Dominguez-Brauer, C. | - |
dc.contributor.author | Elia, A. J. | - |
dc.contributor.author | Berger, T. | - |
dc.contributor.author | Greicius, G. | - |
dc.contributor.author | Pettersson, S. | - |
dc.contributor.author | Mak, T. W. | - |
dc.date.accessioned | 2020-11-17T14:56:02Z | - |
dc.date.available | 2020-11-17T14:56:02Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Oncogene, 2013, v. 32, n. 10, p. 1233-1239 | - |
dc.identifier.issn | 0950-9232 | - |
dc.identifier.uri | http://hdl.handle.net/10722/292231 | - |
dc.description.abstract | Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cancer. Functionally, LCN2 has a number of different activities that may contribute to its oncogenic potential, including increasing matrix metalloproteinase activity, control of iron availability and stimulating inflammation. In this report, we examined APCmin intestinal tumorigenesis in an LCN2-deficient background. We found that the loss of LCN2 increased tumor multiplicity specifically in the duodenum, suggesting a potential tumor-suppressive activity. Concurrently, however, LCN2 increased the average small intestinal tumor size particularly in the distal small intestine. We found that this increase was correlated to tumor iron(II) content, suggesting that an iron-scavenging role is important for LCN2 oncogenic activity in the intestine. © 2013 Macmillan Publishers Limited. | - |
dc.language | eng | - |
dc.relation.ispartof | Oncogene | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | iron | - |
dc.subject | intestinal cancer | - |
dc.subject | 24p3 | - |
dc.subject | NGAL | - |
dc.title | Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/onc.2012.159 | - |
dc.identifier.pmid | 22614012 | - |
dc.identifier.pmcid | PMC3594828 | - |
dc.identifier.scopus | eid_2-s2.0-84874766439 | - |
dc.identifier.volume | 32 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 1233 | - |
dc.identifier.epage | 1239 | - |
dc.identifier.eissn | 1476-5594 | - |
dc.identifier.isi | WOS:000316454500004 | - |
dc.identifier.issnl | 0950-9232 | - |